Icon Bioscience Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 13
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $32M
Latest Deal Amount

Icon Bioscience General Information

Description

Developer of a bio-pharma platform designed to deliver injectable ophthalmic drug-device combination therapeutics. The company's bio-pharma platform focuses on the development and commercialization of novel intraocular therapeutics based on proprietary and patented drug delivery platform, enabling the healthcare professionals to experience a transformational change in the delivery of ophthalmic pharmaceuticals and address the unmet or under-satisfied ophthalmic pharmaceutical needs.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Therapeutic Devices
Primary Office
  • 39899 Balentine Drive
  • Suite 200
  • Newark, CA 94560
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Icon Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 28-Mar-2018 $32M 000.00 0000 Completed Profitable
3. Later Stage VC 01-Dec-2015 00.000 000.00 Completed Profitable
2. Later Stage VC (Series B) 28-Aug-2013 $15M $32M 0000 Completed Clinical Trials - Phase 3
1. Early Stage VC 19-Sep-2007 $17M $17M 000.00 Completed Startup
To view Icon Bioscience’s complete valuation and funding history, request access »

Icon Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series A 000,000 00.000000 00 000.00 000.00 00 000.00 00.000
To view Icon Bioscience’s complete cap table history, request access »

Icon Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a bio-pharma platform designed to deliver injectable ophthalmic drug-device combination therapeutics. The c
Biotechnology
Newark, CA
13 As of 2013
000.00
000 0000-00-00
000000&0 000.00

000000 0

dipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 00000000
Bedford, MA
000 As of 0000
00000
000000 - 000 00000

0000000

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Icon Bioscience Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ocular Therapeutix Formerly VC-backed Bedford, MA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
0000000 000000 Formerly VC-backed Redwood City, CA 00 00000 00000000 00000
000000 000000000 Corporation Oxford, United Kingdom 000 00000 000000000 00000
To view Icon Bioscience’s complete competitors history, request access »

Icon Bioscience Patents

Icon Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210379291-A1 Systems, kits and methods for loading and delivering a small volume dose from a syringe Pending 09-Feb-2018 00000000000
CA-2913336-A1 Use of sustained release dexamethasone in post-cataract surgery inflammation Granted 24-May-2013 0000000000
US-20160120879-A1 Use of sustained release dexamethasone in post-cataract surgery inflammation Granted 24-May-2013 0000000000 0
US-20180303851-A1 Use of sustained release dexamethasone in post-cataract surgery inflammation Granted 24-May-2013 0000000000
JP-2016526039-A Use of sustained-release dexamethasone in inflammation after cataract surgery Granted 24-May-2013 A61K31/573
To view Icon Bioscience’s complete patent history, request access »

Icon Bioscience Executive Team (6)

Name Title Board Seat Contact Info
Howard Franklin MD Vice President, Clinical & Medical Affairs
Cathy Gerlett Vice President, Quality and Compliance
You’re viewing 2 of 6 executive team members. Get the full list »

Icon Bioscience Board Members (3)

Name Representing Role Since
Vernon Wong MD Icon Bioscience Chairman & Founder 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Icon Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Icon Bioscience Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Signet Healthcare Partners Growth/Expansion Minority 000 0000 000000 0
To view Icon Bioscience’s complete investors history, request access »